Original language | English (US) |
---|---|
Pages (from-to) | 1851-1852 |
Number of pages | 2 |
Journal | JACC: Cardiovascular Interventions |
Volume | 14 |
Issue number | 16 |
DOIs | |
State | Published - Aug 23 2021 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: JACC: Cardiovascular Interventions, Vol. 14, No. 16, 23.08.2021, p. 1851-1852.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply
T2 - Multivessel Versus Culprit-Vessel PCI in Patients With NSTEMI and Cardiogenic Shock
AU - Omer, Mohamed A.
AU - Brilakis, Emmanouil S.
AU - Elgendy, Islam Y.
AU - Chan, Paul S.
AU - Spertus, John A.
N1 - Funding Information: Dr Omer has reported that he has no relationships relevant to the contents of this paper to disclose. Dr Brilakis has received consulting fees and/or speaker honoraria from Abbott Vascular, American Heart Association (Associate Editor, Circulation), Amgen, Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), ControlRad, CSI, Ebix, Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; has received research support from Regeneron and Siemens; is an owner of Hippocrates; and is a shareholder of MHI Ventures. Dr Elgendy has received research grants from Caladrius Biosciences unrelated to this manuscript content. Dr Chan is supported by a grant from the National Heart, Lung, and Blood Institute (1R01HL123980). Dr Spertus has received grant funding from the National Institutes of Health, Patient-Centered Outcomes Research Institute, Abbott Vascular, and Bayer; has an equity interest in Health Outcomes Sciences; has a copyright to the Seattle Angina Questionnaire; and has served as a consultant to Novartis, Bayer, United Healthcare, and AstraZeneca. Funding Information: Dr Omer has reported that he has no relationships relevant to the contents of this paper to disclose. Dr Brilakis has received consulting fees and/or speaker honoraria from Abbott Vascular, American Heart Association (Associate Editor, Circulation), Amgen, Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), ControlRad, CSI, Ebix, Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; has received research support from Regeneron and Siemens; is an owner of Hippocrates; and is a shareholder of MHI Ventures. Dr Elgendy has received research grants from Caladrius Biosciences unrelated to this manuscript content. Dr Chan is supported by a grant from the National Heart, Lung, and Blood Institute (1R01HL123980). Dr Spertus has received grant funding from the National Institutes of Health, Patient-Centered Outcomes Research Institute, Abbott Vascular, and Bayer; has an equity interest in Health Outcomes Sciences; has a copyright to the Seattle Angina Questionnaire; and has served as a consultant to Novartis, Bayer, United Healthcare, and AstraZeneca.
PY - 2021/8/23
Y1 - 2021/8/23
UR - http://www.scopus.com/inward/record.url?scp=85112593481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112593481&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2021.07.013
DO - 10.1016/j.jcin.2021.07.013
M3 - Letter
C2 - 34412807
AN - SCOPUS:85112593481
SN - 1936-8798
VL - 14
SP - 1851
EP - 1852
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 16
ER -